GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
56.66
+0.67 (1.20%)
Apr 2, 2026, 11:41 AM EDT - Market open
GSK Market Cap
GSK has a market cap or net worth of $112.19 billion as of April 2, 2026. Its market cap has increased by 36.13% in one year.
Market Cap
112.19B
Enterprise Value
130.76B
1-Year Change
36.13%
Ranking
Category
Stock Price
$56.66
Market Cap Chart
Since December 1, 1998, GSK's market cap has decreased from $159.34B to $112.19B, a decrease of -29.59%. That is a compound annual growth rate of -1.27%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 1, 2026 | 114.09B | 15.34% |
| Dec 31, 2025 | 98.91B | 44.25% |
| Dec 31, 2024 | 68.57B | -8.74% |
| Dec 29, 2023 | 75.14B | 6.12% |
| Dec 30, 2022 | 70.81B | -35.88% |
| Dec 31, 2021 | 110.43B | 20.28% |
| Dec 31, 2020 | 91.81B | -21.29% |
| Dec 31, 2019 | 116.64B | 23.14% |
| Dec 31, 2018 | 94.72B | 8.77% |
| Dec 29, 2017 | 87.08B | -7.13% |
| Dec 30, 2016 | 93.77B | -4.44% |
| Dec 31, 2015 | 98.13B | -5.42% |
| Dec 31, 2014 | 103.75B | -21.06% |
| Dec 31, 2013 | 131.43B | 19.76% |
| Dec 31, 2012 | 109.74B | -7.43% |
| Dec 30, 2011 | 118.55B | 16.46% |
| Dec 31, 2010 | 101.79B | -7.10% |
| Dec 31, 2009 | 109.58B | 17.51% |
| Dec 31, 2008 | 93.25B | -31.55% |
| Dec 31, 2007 | 136.24B | -6.62% |
| Dec 29, 2006 | 145.90B | 52.77% |
| Dec 31, 2002 | 95.50B | -24.81% |
| Dec 31, 2001 | 127.01B | -11.04% |
| Dec 29, 2000 | 142.77B | 0.22% |
| Dec 31, 1999 | 142.45B | -19.60% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AbbVie | 384.69B |
| AstraZeneca | 300.86B |
| Merck & Co. | 297.40B |
| Novartis AG | 287.51B |
| Amgen | 189.67B |
| Gilead Sciences | 172.99B |
| Pfizer | 159.73B |
| Novo Nordisk | 158.15B |